Abbvie (ABBV) Reiterated Overweight at Morgan Stanley Ahead of Rinvoq vs Dupixent Head to Head Trial Results
Tweet Send to a Friend
Morgan Stanley analyst David Risinger reiterated an Overweight rating and $108.00 price target on Abbvie (NYSE: ABBV) ahead of expected ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
